Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Female
HSP90 Heat-Shock Proteins
Humans
Male
Melanoma
Middle Aged
Skin Neoplasms
Triazoles
Uveal Neoplasms